Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 in Melanoma

PR NewswireMarch 03, 2025

Tag: Innovent , IBI363 , Melanoma

PharmaSources Customer Service